CAS No. : 465-65-6

Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000007
Synonyms:17-Allyl-4,5α-epoxy-3,14-dihydroxy-morphinan-6-one; (5α)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; N-Allyl-7,8-dihydro-14-hydroxynormorphinone, (7CI); (-)-Naloxone; 12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophena
Molecular Formula:C19H21NO4
Molecular Weight:327.38
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

Appearance:Solid powder
Purity: > 98%
Cat No:I000007
Cas No:465-65-6
IUPAC Name:(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one
Naloxone is useful both in acute opioid overdose and in reducing respiratory or mental depression due to opioids. It is included as a part of emergency overdose response kits distributed to heroin and other opioid drug users, and this has been shown to reduce rates of deaths due to overdose. Naloxone cannot be absorbed via the GI tract, so it is commonly combined with a number of oral opioid preparations, including buprenorphine and pentazocine, so that when taken orally just the opioid has an effect; but if misused by injecting, the naloxone blocks the effect of the opioid. This combination is used in an effort to prevent abuse.

1:Geraniin attenuates naloxone-precipitated morphine withdrawal and morphine-induced tolerance in mice. Kasanga EA, Boakye-Gyasi E, Biney RP, Kyekyeku JO, Agyare C, Woode E.J Intercult Ethnopharmacol. 2017 Feb 18;6(2):199-205. doi: 10.5455/jice.20161229015413. eCollection 2017 Apr-Jun. PMID: 28507784 Free PMC Article
2:Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-Generating Small Clinical Studies. Gufford BT, Ainslie GR, White JR Jr, Layton ME, Padowski JM, Pollack GM, Paine MF.Clin Transl Sci. 2017 May 15. doi: 10.1111/cts.12473. [Epub ahead of print] PMID: 28504483
3:Validated Spectrophtometric Method for Simultaneous Determination of Buprenorphine and Naloxone in Pharmaceutical Dosage Forms. Souri E, Ahmadi FS, Barazandeh Tehrani M, Hosseini MM, Fadaye Vatan S.Iran J Pharm Res. 2017 Winter;16(1):112-119. PMID: 28496466 Free PMC Article
4:Medical providers/' knowledge and concerns about opioid overdose education and take-home naloxone rescue kits within Veterans Affairs health care medical treatment settings. Winograd RP, Davis CS, Niculete M, Oliva E, Martielli RP.Subst Abus. 2017 Apr-Jun;38(2):135-140. doi: 10.1080/08897077.2017.1303424. PMID: 28486076
5:Multiple Naloxone Administrations Among Emergency Medical Service Providers is Increasing. Faul M, Lurie P, Kinsman JM, Dailey MW, Crabaugh C, Sasser SM.Prehosp Emerg Care. 2017 May 8:1-8. doi: 10.1080/10903127.2017.1315203. [Epub ahead of print] PMID: 28481656
6:Treatment of opioid overdose: a brief review of naloxone pharmacology and delivery. Hendley TM, Hersh EV, Moore PA, Stahl B, Saraghi M.Gen Dent. 2017 May-Jun;65(3):18-21. No abstract available. PMID: 28475079
7:Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study. Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M.Eur J Pain. 2017 May 4. doi: 10.1002/ejp.1050. [Epub ahead of print] PMID: 28474460
8:A trial of naloxone for peer administration has merit, but will the lawyers let it happen? Lenton S, Hargreaves K.Drug Alcohol Rev. 2000 Dec;19(4):365-369. doi: 10.1080/713659423. No abstract available. PMID: 28474443
9:High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain. Amato F, Ceniti S, Mameli S, Pisanu GM, Vellucci R, Palmieri V, Consoletti L, Magaldi D, Notaro P, Marcassa C.Support Care Cancer. 2017 May 3. doi: 10.1007/s00520-017-3709-5. [Epub ahead of print] PMID: 28470370
10:Correction: Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal. [No authors listed]Ann Intern Med. 2017 May 2;166(9):687. doi: 10.7326/M17-0652. No abstract available. PMID: 28460394
Recommended Products
  • CAS No. :2550-26-7
    Product Name:


    Cat No: R015865 View details
  • CAS No. :1517-22-2
    Product Name:


    Cat No: R015866 View details
  • CAS No. :84508-55-4
    Product Name:

    Ethyl Acetoacetate-13C4

    Cat No: R015867 View details
  • CAS No. :36768-62-4
    Product Name:


    Cat No: R015868 View details